Deals

Healthtech deals decreased significantly in the pharma industry in H1 2022

The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.

In that time period, deals relating to healthtech accounted for 12.8% of all deals taking place in the sector.

Powered by 

In the first half of 2022 the number of deals relating to healthtech decreased significantly by 28.7% from the same period in 2021. 

This marks an acceleration in growth from the 34.7% decrease in deals that occurred in H2 2021 relative to the same period a year earlier. 

GlobalData's deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.

During first half of 2022, deals relating to healthtech accounted for 12.8% of all deals taking place in the sector. This represents a decrease from the figure of 14.6% in the first half of 2021.

GlobalData's thematic approach to sector activity seeks to group key company information on investments to see which industries are best placed to deal with any issues they may encounter. 

These themes, of which healthtech is one, are best thought of as "any issue that keeps a CEO awake at night", and by tracking them, it becomes possible to ascertain which companies are leading the way on specific issues and which ones have some work to do.

Go to article: Home | Technology transformationGo to article: In this issueGo to article: ContentsGo to article: SHL Medical Company Insight Go to article: SHL MedicalGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: CSafe GlobalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CommentGo to article: Tapping into pharma’s growing opportunities in digital healthGo to article: Covid-19 Omicron boosters will reinvigorate injectables manufacturingGo to article: Implementation of electronic health records will improve the quality of careGo to article: Despite benefits, long-acting injectables remain underutilised for schizophreniaGo to article: FDA approves Coherus’ Cimerli for DME, with year-long interchangeability exclusivityGo to article: UK health data collaboration paves the way to study Long Covid symptomsGo to article: Molnar-Institute Company Insight Go to article: Molnar-InstituteGo to article: In DepthGo to article: A makeover for NICE: a new look for HTAs in the UK Go to article: No drugs for prions: investigating new approaches to alleviate therapeutic scarcGo to article: Getting smart with digital pillsGo to article: Do generics producers have what it takes to tackle complex and specialty drugs?Go to article: Decentralised paediatric clinical trials trending up but study execution criticaGo to article: CMO Moves: Regulatory catalysts for drug manufacturing—August Go to article: Biolife SolutionsGo to article: In DataGo to article: Healthtech deals decreased significantly in the pharma industry in H1 2022Go to article: North America is seeing a hiring boom in pharmaceutical industry machine learninGo to article: Artificial intelligence mentions decrease in pharma filings in Q2 of 2022Go to article: Digital media hiring levels in the pharmaceutical industry rose in June 2022Go to article: EventsGo to article: Next issue